

Comparison of Michigan Interchangeable Biological Product Substitution Bills

Provisions To Consider	HB 4812 (Rep. Bizon)	HB 4437 (Rep. Yonker)
Follows FDA guidelines that only interchangeable biosimilars should be substituted?	YES	NO
Requires the pharmacy to notify the prescriber after an interchangeable biosimilar is dispensed?	YES	NO
Supported by MSMS, MSHO, national specialty physician groups, and patient groups like the American Cancer Society and Arthritis Foundation?	YES	NO
Supported by the Alliance for Safe Biologic Medicines?	YES	NO
Is the national biosimilars coalition model bill language?	YES	NO
Is the same model language recently passed in other states?	YES	NO
Promotes substitution/switching of biosimilar products that have not been approved by the FDA as substitutable?	NO	YES
Retains prescriber dispense as written (DAW) authority?	YES	YES
Requires that the patient be notified when an interchangeable biosimilar is substituted?	YES	YES
Would interfere with a health plan's ability to use cost containment tools and manage formularies?	NO	NO